Discussion on rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production

Gastroenterology

Volumn 120, Issue 4, 2001, Pages 867-873

  Hawkey, C J ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NAPROXEN; PLACEBO; ROFECOXIB;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFECT; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; MALE; MOUTH ULCER; PAIN; PHARYNGITIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; STOMACH BIOPSY; STOMACH EROSION; STOMACH MUCOSA;

EID: 0035120196     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.29469     Document Type: Article

References (31)

1. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study
2. Non-steroidal anti-inflammatory drugs and peptic ulcers
3. Quantitative estimation of rare adverse events which follow a biological progression: A new model applied to chronic NSAID use
4. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use
5. Nonsteroidal antiinflammatory drug-associated gastropathy: Incidence and risk factor models
6. Epidemiology of NSAID-induced GI complications
7. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
8. Cyclooxygenase (COX)-1 and -2 in normal, inflamed and ulcerated human gastric mucosa
9. Mechanism of action of non-steroidal antiinflammatory drugs
10. COX-2 inhibitors
11. Celecoxib: A COX-2 inhibitor for the treatment of osteoarthritis and rheumatoid arthritis
12. Rofecoxib
13. Antiinflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomised controlled trial
14. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of osteoarthritis patients
15. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
16. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
17. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
18. Biochemical and pharmacological characterisation of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases
19. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
20. 2) synthesis in healthy humans
21. Evidence that the COX-2 specific inhibitor rofecoxib at 50 mg spares gastric mucosal prostaglandin synthesis in humans
22. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa
23. Separation of the impairment of haemostasis by aspirin from mucosal injury in the human stomach
24. Protection of human gastric mucosa against aspirin - Enteric coating or dose reduction?
25. Two comparative endoscopic evaluations of naprelan
26. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs
27. Gastric tolerability of S(+) ibuprofen compared to racemic ibuprofen
28. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen aspirin and other nonsteroidal anti-inflammatory agents
29. Effect of Helicobacter pylori infection on the severity of gastroduodenal mucosal injury after the acute administration of naproxen or aspirin to normal volunteers
30. Preliminary study of the safety and efficacy of SC-58635 a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis and studies of gastrointestinal and platelet effects
31. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis